Antifibrotic therapies: Will we ever get there?

Current Gastroenterology Reports

Volumn 12, Issue 1, 2010, Pages 23-29

  Thompson, Alexander James ^a   Patel, Keyur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifibrotic; Fibrosis; Hepatic stellate cell; Liver; Therapy

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALPHA INTERFERON; ALPHAVBETA6 INTEGRIN INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN[1-7]; ANTIFIBROTIC AGENT; BERBERINE; CANDESARTAN; CASPASE INHIBITOR; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FARGLITAZAR; GAMMA INTERFERON; GS 9450; INCHINKO TO; INT 747; IRBESARTAN; LOSARTAN; PEGINTERFERON ALPHA; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PF 03491390; PIOGLITAZONE; PIRFENIDONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SILYMARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 166;

ALTERNATIVE MEDICINE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COFFEE; DRUG EFFICACY; DRUG MECHANISM; FIBROGENESIS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SILYBUM MARIANUM; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II; CASPASES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; LIVER CIRRHOSIS; PPAR GAMMA;

EID: 77950860535     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0080-9     Document Type: Review

References (49)

1. United Network for Organ Sharing: Online database system. Available at http://www.unos.org/data/. Accessed November 2009.
2. SL Friedman 2008 Mechanisms of hepatic fibrogenesis Gastroenterology 134 1655 1669 10.1053/j.gastro.2008.03.003 18471545 1:CAS:528:DC%2BD1cXntF2gs7o%3D (Pubitemid 351615417)
3. H Jaeschke 2002 Inflammation in response to hepatocellular apoptosis Hepatology 35 964 966 10.1053/jhep.2002.0350964 11915046
4. E Seki S De Minicis CH Osterreicher, et al. 2007 TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 13 1324 1332 10.1038/nm1663 17952090 1:CAS:528:DC%2BD2sXht1Kmtr3O This study showed that TLR4 expression and signaling by HSCs is an important fibrogenic stimulus (Pubitemid 350073596)
5. WA Border NA Noble 1994 Transforming growth factor beta in tissue fibrosis N Engl J Med 331 1286 1292 10.1056/NEJM199411103311907 7935686 1:CAS:528:DyaK2MXitlGksrs%3D (Pubitemid 24333194)
6. T Nakamura R Sakata T Ueno, et al. 2000 Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats Hepatology 32 247 255 10.1053/jhep.2000.9109 10915731 1:CAS:528:DC%2BD3cXlvVyjt74%3D
7. E Borkham-Kamphorst CR van Roeyen T Ostendorf, et al. 2007 Pro-fibrogenic potential of PDGF-D in liver fibrosis J Hepatol 46 1064 1074 10.1016/j.jhep.2007.01.029 17397961 1:CAS:528:DC%2BD2sXkvFGjsbo%3D (Pubitemid 46669736)
8. S Yokohama M Yoneda M Haneda, et al. 2004 Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis Hepatology 40 1222 1225 10.1002/hep.20420 15382153 1:CAS:528:DC%2BD2cXhtVCgt7jK (Pubitemid 39425579)
9. L Yang R Bataller J Dulyx, et al. 2005 Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice J Hepatol 43 317 323 10.1016/j.jhep.2005.02.034 15964094 1:CAS:528:DC%2BD2MXlvFalsL0%3D (Pubitemid 40956886)
10. K Ikejima Y Takei H Honda, et al. 2002 Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat Gastroenterology 122 1399 1410 10.1053/gast.2002.32995 11984526 1:CAS:528:DC%2BD38Xkt1Cru7k%3D
11. A Mallat F Teixeira-Clerc V Deveaux S Lotersztajn 2007 Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases Expert Opin Ther Targets 11 403 409 10.1517/14728222.11.3.403 17298297 (Pubitemid 46290962)
12. B Wang BM Dolinski N Kikuchi, et al. 2007 Role of alphavbeta6 integrin in acute biliary fibrosis Hepatology 46 1404 1412 10.1002/hep.21849 17924447 1:CAS:528:DC%2BD2sXhtlOiu7jF (Pubitemid 350155522)
13. L Ulloa J Doody J Massague 1999 Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway Nature 397 710 713 10.1038/17826 10067896 1:CAS:528:DyaK1MXhs1ekurc%3D (Pubitemid 29108392)
14. Y Kamada S Tamura S Kiso, et al. 2003 Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin Gastroenterology 125 1796 1807 10.1053/j.gastro.2003.08.029 14724832 1:CAS:528:DC%2BD2cXhtVOqtg%3D%3D (Pubitemid 37500444)
15. M Adachi DA Brenner 2008 High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase Hepatology 47 677 685 10.1002/hep.21991 18220291 1:CAS:528:DC%2BD1cXitF2lu7k%3D (Pubitemid 351280736)
16. F Marra E Efsen RG Romanelli, et al. 2000 Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells Gastroenterology 119 466 478 10.1053/gast.2000.9365 10930382 1:CAS:528:DC%2BD3cXmtVWrurY%3D
17. A Galli DW Crabb E Ceni, et al. 2002 Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 122 1924 1940 10.1053/gast.2002.33666 12055599 1:CAS:528:DC%2BD38Xlt12gsLw%3D
18. S Fiorucci G Rizzo E Antonelli, et al. 2005 Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis J Pharmacol Exp Ther 315 58 68 10.1124/jpet.105.085597 15980055 1:CAS:528:DC%2BD2MXhtVOksrfJ (Pubitemid 41380498)
19. WK Syn Y Jung A Omenetti, et al. 2009 Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease Gastroenterology 137 1478 1488 10.1053/j.gastro.2009.06.051 19577569 1:CAS:528:DC%2BD1MXht12gtr3N
20. T Poynard J McHutchison M Manns, et al. 2002 Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 1303 1313 10.1053/gast.2002.33023 11984517 1:CAS:528:DC%2BD38Xkt1Cru74%3D
21. S Bruno T Stroffolini M Colombo, et al. 2007 Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 579 587 10.1002/hep.21492 17326216 1:CAS:528:DC%2BD2sXjs1Gktbc%3D (Pubitemid 46453759)
22. BJ Veldt EJ Heathcote H Wedemeyer, et al. 2007 Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 677 684 18025443
23. JL Dienstag ER Schiff TL Wright, et al. 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263 10.1056/NEJM199910213411702 10528035 1:CAS:528:DyaK1MXnt1Cqs78%3D (Pubitemid 29489740)
24. SJ Hadziyannis NC Tassopoulos EJ Heathcote, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1743 1751 10.1053/j.gastro.2006.09.020 17087951 1:CAS:528:DC%2BD2sXhtFyltLs%3D (Pubitemid 44958517)
25. JL Dienstag RD Goldin EJ Heathcote, et al. 2003 Histological outcome during long-term lamivudine therapy Gastroenterology 124 105 117 10.1053/gast.2003.50013 12512035 1:CAS:528:DC%2BD3sXot1antQ%3D%3D (Pubitemid 36055344)
26. L Falize A Guillygomarc'h M Perrin, et al. 2006 Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases Hepatology 44 472 477 10.1002/hep.21260 16871557 (Pubitemid 44214887)
27. LW Powell JL Dixon GA Ramm, et al. 2006 Screening for hemochromatosis in asymptomatic subjects with or without a family history Arch Intern Med 166 294 301 10.1001/archinte.166.3.294 16476869 (Pubitemid 43244317)
28. JF Dufour R DeLellis MM Kaplan 1997 Reversibility of hepatic fibrosis in autoimmune hepatitis Ann Intern Med 127 981 985 9412303 1:STN:280: DyaK1c%2FjtF2ltQ%3D%3D
29. SJ Cotler S Jakate DM Jensen 2001 Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy J Clin Gastroenterol 32 428 430 10.1097/00004836-200105000-00014 11319316 1:STN:280:DC%2BD3M3jtFSksw%3D%3D (Pubitemid 32378277)
30. JB Dixon PS Bhathal NR Hughes PE O'Brien 2004 Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss Hepatology 39 1647 1654 10.1002/hep.20251 15185306 (Pubitemid 38702666)
31. RR Mummadi KS Kasturi S Chennareddygari GK Sood 2008 Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis Clin Gastroenterol Hepatol 6 1396 1402 10.1016/j.cgh.2008.08.012 18986848
32. F Saez-Royuela JC Porres A Moreno, et al. 1991 High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial Hepatology 13 327 331 10.1002/hep.1840130220 1899852 1:STN:280:DyaK3M7jvFSltA%3D%3D
33. AJ Muir PB Sylvestre DC Rockey 2006 Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection J Viral Hepat 13 322 328 10.1111/j.1365-2893.2005.00689.x 16637863 1:STN:280:DC%2BD283jt1SjtA%3D%3D
34. HL Weng BE Wang JD Jia, et al. 2005 Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study Clin Gastroenterol Hepatol 3 819 828 10.1016/S1542-3565(05)00404-0 16234012 1:CAS:528:DC%2BD2MXhtVWjtLnP (Pubitemid 41116736)
35. PJ Pockros L Jeffers N Afdhal, et al. 2007 Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis Hepatology 45 569 578 10.1002/hep.21561 17326152 1:CAS:528: DC%2BD2sXjs1GktbY%3D Multicenter randomized controlled study failed to show a histologic benefit with the use of IFN-γ (Pubitemid 46450609)
36. AM Di Bisceglie ML Shiffman GT Everson, et al. 2008 Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2429 2441 10.1056/NEJMoa0707615 19052125 This study (HALT-C, along with the EPIC-3 and COPILOT studies) demonstrated that there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis
37. T Poynard M Colombo J Bruix, et al. 2009 Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 1618 1628 10.1053/j.gastro.2009.01. 039 19208349 1:CAS:528:DC%2BD1MXmtFWqu70%3D This study (EPIC-3, along with the HALT-C and COPILOT studies) demonstrated that there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis
38. N Afdhal R Levine RJ Brown, et al. 2008 E. Colchicine vs peg-interferonalfa 2B long term therapy: results of the 4 year COPILOT trial J Hepatol 48 Suppl 2 S4 (A3) This study (COPILOT, and the HALT-C and EPIC-3 studies) demonstrated there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis
39. L Yang CC Chan OS Kwon, et al. 2006 Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis Am J Physiol Gastrointest Liver Physiol 291 G902 G911 10.1152/ajpgi.00124.2006 16798724 1:CAS:528:DC%2BD28Xht1GnsLzJ (Pubitemid 44772017)
40. J McHutchison Z Goodman H Makhlouf, et al. 2008 Double-blind, randomized, placebo-controlled, multi-center, phase II dose-ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection Hepatology 48 4 Suppl 1139A
41. Colmenero J, Bataller R, Sancho-Bru P, et al.: Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009 (Epub ahead of print).
42. PJ Pockros ER Schiff ML Shiffman, et al. 2007 Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C Hepatology 46 324 329 10.1002/hep.21664 17654603 1:CAS:528:DC%2BD2sXhtVSisb7J (Pubitemid 47344766)
43. RP Witek WC Stone FG Karaca, et al. 2009 Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis Hepatology 50 1421 1430 10.1002/hep.23167 19676126 1:CAS:528:DC%2BD1MXhsV2js7%2FN
44. E Patsenker Y Popov F Stickel, et al. 2008 Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression Gastroenterology 135 660 670 10.1053/j.gastro.2008.04.009 18538673 1:CAS:528:DC%2BD1cXhtVCqsL3O This study demonstrated that inhibitors (v(6 integrin have antifibrotic potential
45. J Munoz-Luque J Ros G Fernandez-Varo, et al. 2008 Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats J Pharmacol Exp Ther 324 475 483 10.1124/jpet.107.131896 18029545 1:CAS:528:DC%2BD1cXhsFShtrk%3D (Pubitemid 351185849)
46. F Teixeira-Clerc B Julien P Grenard, et al. 2006 CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis Nat Med 12 671 676 10.1038/nm1421 16715087 1:CAS:528:DC%2BD28XltlOjtrw%3D (Pubitemid 43865236)
47. A Douglass K Wallace R Parr, et al. 2008 Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury J Hepatol 49 88 98 10.1016/j.jhep.2008.01.032 18394744 1:CAS:528:DC%2BD1cXmvFelsL4%3D
48. ND Freedman JE Everhart KL Lindsay, et al. 2009 Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C Hepatology 50 1360 1369 10.1002/hep.23162 19676128 1:CAS:528:DC%2BD1MXhsV2js77M
49. Y Popov D Schuppan 2009 Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies Hepatology 50 1294 1306 10.1002/hep.23123 19711424 1:CAS:528:DC%2BD1MXhtlWksr%2FM